Related Experiment Video

Updated: Jul 18, 2026

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions
10:24

In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions

Published on: June 11, 2015

Staphylococcal secretory inhibitor of platelet microbicidal protein is associated with prostatitis source

Iuri B Ivanov1, Viktor A Gritsenko1, Michael D Kuzmin1

  • 1Department of Human Microbiology, Institute of Cellular and Intracellular Symbiosis, Russian Academy of Sciences, Orenburg, Russia.

Journal of Medical Microbiology
|November 17, 2006
PubMed

Insights

Researchers discovered a staphylococcal product, secretory inhibitor of platelet microbicidal protein (SIPMP), that hinders bacterial killing. SIPMP production was higher in bacteria from chronic bacterial prostatitis patients, suggesting a role in this infection.

Area of Science:

  • Microbiology
  • Immunology
  • Urology

Background:

  • Platelet microbicidal proteins (PMPs) are crucial for innate immunity against bacterial infections.
  • Staphylococcus aureus and coagulase-negative staphylococci (CNS) are common causes of urinary tract infections, including chronic bacterial prostatitis (CBP).
  • Mechanisms by which staphylococci evade PMP-mediated killing are not fully understood.

Purpose of the Study:

  • To identify and characterize staphylococcal factors that inhibit PMP activity.
  • To investigate the association between the production of this inhibitor and chronic bacterial prostatitis (CBP).

Main Methods:

  • Detection of an extracellular staphylococcal product, secretory inhibitor of platelet microbicidal protein (SIPMP), by its ability to inhibit PMP bioactivity against Bacillus subtilis.
  • Quantification of SIPMP production as percentage inhibition of PMP bactericidal activity.
  • Determination of PMP susceptibility of Staphylococcus aureus and CNS strains isolated from patients with or without CBP.

Main Results:

  • Staphylococcal strains isolated from patients with CBP produced significantly higher levels of SIPMP compared to those from patients without CBP.
  • SIPMP production strongly correlated with staphylococcal resistance to PMP-mediated killing.
  • This study identified SIPMP as a novel staphylococcal virulence factor.

Conclusions:

  • SIPMP is a newly identified staphylococcal product that inhibits the bactericidal activity of PMP.
  • Increased SIPMP production by staphylococci is associated with chronic bacterial prostatitis (CBP).
  • SIPMP may represent a significant determinant of staphylococcal pathogenicity in CBP and warrants further investigation.

More Related Videos

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP06:36

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Published on: April 9, 2013

Related Concept Videos

Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Determinants of Bacterial Pathogenicity and Virulence01:20

Determinants of Bacterial Pathogenicity and Virulence

Pathogenic bacteria employ a variety of strategies to establish infections, including the secretion of extracellular enzymes that act as potent virulence factors. These enzymes facilitate bacterial colonization of host tissues and help evade immune surveillance. By targeting structural components of host tissues and interfering with immune mechanisms, these enzymes play a pivotal role in disease progression.Extracellular Enzymes Facilitating Tissue Invasion: Several bacterial pathogens secrete...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...